Hyderabad-Based Hetero Gets Regulatory Nod To Make Gilead's COVID-19 Drug
Hyderabad-based drug maker Hetero said on Sunday that it had received approval of regulator Drug Controller General of India (DCGI) to manufacture and market investigational antiviral medicine Remdesivir for the treatment of COVID-19 disease. The company said in a press release that its generic version of US-based Gilead Science's experimental COVID-19 treatment Remdesivir will be marketed under brand name Covifor in India. Covifor will be available in 100 milligram vials (injectable) which have to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner, it said.
Hetero said the product is launched under a licensing agreement with Gilead Sciences to expand access to COVID-19 treatment in low- and middle-income countries.
"In the light of increasing COVID-19 cases in India, the approval of Covifor (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country," said Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies.
"We are prepared for ensuring enough stocks required to cater to the present needs. We will continue to work closely with the government and medical community to make a difference in the fight against COVID-19," he said.
Hetero said Covifor will likely be priced at Rs 5,000-6,000 for a 100-mg dose, news agency Reuters reported.
Remdesivir has received approval of the country's drug regulator "for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease", Hetero said.Â
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.